The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma

G. F. Laport*, S. F. Williams

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations

Abstract

Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term survival. High-dose chemotherapy (HDC) with stem cell rescue has emerged as the treatment of choice for such patients as long-term disease-free survival can be obtained in a significant number of these patients. Dose-intensive treatment has been equivocally shown effective for certain patients with Hodgkin's and NHL, whether or not chemosensitivity is shown before transplant. However, HDC has yet to consistently yield durable responses in patients with indolent NHL. Additionally, perhaps the International Prognostic Index can now help identify 'high-risk' NHL patients who may benefit from investigative approaches such as frontline HDC.

Original languageEnglish (US)
Pages (from-to)503-517
Number of pages15
JournalSeminars in Oncology
Volume25
Issue number4
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this